Johnson & Johnson Aktie News

It is possible to build wealth through dividend investing. While it isn't guaranteed that your investment will grow, you'll continue to enjoy passive income as long as you hold the stock.

Healthcare may be entering early mean reversion, but much of Johnson & Johnson's valuation recovery has already occurred. Post-Kenvue, JNJ is a higher-growth, less dividend-centric business, changing how income investors should evaluate the stock. Free cash flow momentum has improved, supporting reinvestment and potential multiple expansion if execution continues.

Johnson & Johnson is downgraded to Hold, as valuation is now stretched after a 50% 12-month rally. JNJ trades above 21x forward EPS, exceeding its long-term average and offering a limited margin of safety despite strong fundamentals. Q3 results were robust, with $24B in revenue and a 69.6% gross margin; management raised FY25 sales guidance and maintains an operational EPS outlook.

AbbVie has increased its dividend by 333% since 2013. Coca-Cola is a Dividend King that still has plenty of growth potential.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline...

New CAPLYTA ® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATO ® (esketamine) effects on anhedonia in treatment-resistant depression (TRD) – Phase 3 data post-hoc analyses to be presented Comparative tolerability of adjunctive seltorexant vs. adjunctive quetiapine XR in major depressive disorder (M...

Paying dividends is a priority for both companies. Procter & Gamble has paid dividends for 135 years.